Leukemia Clinical Trials in Pennsylvania

Showing 1241-1260 of 1,719 trials

Clofarabine, Etoposide, and Mitoxantrone for Relapsed and Refractory Acute Leukemias

NCT00882076

The purpose of this study is to establish toxicity and a maximum tolerated dose recommended phase 2 dose of Clofarabine in combination with Etoposide and Mitoxantrone for therapy of relapsed or refractory acute leukemias. The investigators will observe responses with these therapy agents and assess the impact of Clofarabine interacting with Etoposide in induction of DNA strand breaks.

Leukemia

Milton S. Hershey Medical Center22 participantsStarted Mar 2009

Hershey, Pennsylvania, United States

TERMINATEDPhase 136 miles

Bortezomib (PS-341) in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer

NCT00714246

This is a phase I/II study. The phase I portion of the study will determine the maximum tolerated dose of bortezomib when administered in combination with carboplatin \& docetaxel and to determine the efficacy of the combination for patients with advanced NSCLC. Phase II will utilize the dosage determined in the Phase I and implement regimen to determine time to progression, overall survival, and changes in serum proteomics patterns before \& after combination therapy.

Non Small Cell Lung Cancer

Milton S. Hershey Medical Center6 participantsStarted Oct 2008

Hershey, Pennsylvania, United States

Clofarabine, Etoposide, and Mitoxantrone for Relapsed and Refractory Acute Leukemias

Bortezomib (PS-341) in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer

Leukemia Trials in Other Cities

Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)

Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Registry for Integrative Medicine Interventions Effectiveness

Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma

A Study of LY2510924 in Participants With Extensive-Stage Small Cell Lung Carcinoma

PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib

A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia

Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas

BAY1436032 in Patients With Mutant IDH1(mIDH1) Advanced Acute Myeloid Leukemia (AML)

Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML

A Dose-Finding Study of Vedolizumab for Treatment of Steroid-Refractory Acute Intestinal Graft-Versus-Host Disease (GvHD) in Participants Who Have Undergone Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)

Frequency of Screening and SBT Technique Trial

Comparability and Standardization of Controlled Allergen Challenge Facilities

Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia

Laboratory-Treated Lymphocyte Infusion After Haploidentical Donor Stem Cell Transplant

A Study for Patients With Acute Leukemia

Other Conditions in Pennsylvania